BR1015 not checked
Boryung Pharmaceutical Co., Ltd
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Essential Hypertension (4 trials)
- Main trialPhase 1
- “The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-1 and BR1015-2 in healthy volunteers under fasting conditions”In the company’s words, NCT07421375 on ClinicalTrials.gov
Other drugs for Essential Hypertension
- BR1019Boryung Pharmaceutical Co., Ltd · Phase 3
- Valsartan Oral SolutionShandong New Time Pharmaceutical Co., LTD · Phase 3
- AD-227AAddpharma Inc. · Phase 3
- AD-227BAddpharma Inc. · Phase 3
- QR12000Wuhan Createrna Science and Technology Co., Ltd · Phase 3
- Sacubitril∙ValsartanChong Kun Dang Pharmaceutical · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 31 May 2026 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions | |
| Phase 1Not yet recruiting | 7 Jun 2026 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fed Conditions | |
| Phase 1Not yet recruiting | 11 Jun 2026 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions | |
| Phase 1Not yet recruiting | 17 Jun 2026 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions | |
| Phase 1Completed | 3 Oct 2023 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers | |
| Phase 1Completed | 6 Oct 2023 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fasting Conditions in Healthy Volunteers | |
| Phase 1Completed | 12 Mar 2025 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions | |
| Phase 1Completed | 14 Mar 2025 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions | |
| Phase 1Completed | 16 Mar 2025 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions | |
| Phase 1Completed | 19 Mar 2025 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 in Healthy Volunteers Fed Conditions |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026